How RWE can help Biotechs optimize the value of their asset
Traditionally, real-world data (RWD) and real-world evidence (RWE) have not been viewed as critical components to be incorporated into the drug development journey to demonstrate value for market access and product launch/commercialization. With the majority of small and emerging biotech companies choosing to seek out partnership or licensing deals to support pivotal trials and ultimately commercialization of their asset, there was little exposure to the numerous benefits RWD and RWE can provide to these companies early in their development planning and execution.